about
188Re(V) Nitrido Radiopharmaceuticals for Radionuclide Therapy.Psychostimulant Effect of the Synthetic Cannabinoid JWH-018 and AKB48: Behavioral, Neurochemical, and Dopamine Transporter Scan Imaging Studies in Mice.Preparation and first biological evaluation of novel Re-188/Tc-99m peptide conjugates with substance-P.Recent achievements in Tc-99m radiopharmaceutical direct production by medical cyclotrons.Biodistribution of nanostructured lipid carriers: a tomographic study.Monoclonal Antibodies Radiolabeling with Rhenium-188 for Radioimmunotherapy.Chemistry of the strong electrophilic metal fragment [(99)Tc(N)(PXP)](2+) (PXP = diphosphine ligand). A novel tool for the selective labeling of small molecules.High-yield synthesis of the terminal 188Re triple bond N multiple bond from generator-produced [188ReO4](-).The [(99m)Tc(N)(PNP)](2+) metal fragment: a technetium-nitrido synthon for use with biologically active molecules. The N-(2-methoxyphenyl)piperazyl-cysteine analogues as examples.A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma.Bradykinin B₂ receptors increase hippocampal excitability and susceptibility to seizures in mice.Mixed tridentate π -donor and monodentate π -acceptor ligands as chelating systems for rhenium-188 and technetium-99m nitrido radiopharmaceuticals.Influence of Storage Temperature on Radiochemical Purity of 99mTc-Radiopharmaceuticals.A solvent-extraction module for cyclotron production of high-purity technetium-99m.The emerging role of copper-64 radiopharmaceuticals as cancer theranostics.In-house cyclotron production of high-purity Tc-99m and Tc-99m radiopharmaceuticalsRhenium(V) and Technetium(V) Nitrido Complexes with Mixed Tridentate π-Donor and Monodentate π-Acceptor LigandsDesign and Synthesis of TcN-Labeled Dextran-Mannose Derivatives for Sentinel Lymph Node DetectionLARAMED: A Laboratory for Radioisotopes of Medical InterestPerspectives on the Use of Liquid Extraction for Radioisotope PurificationCorrection: Uccelli, L., et al. Therapeutic Radiometals: Worldwide Scientific Literature Trend Analysis (2008⁻2018). 2019, , 640Interdisciplinary Tasks in the Cyclotron Production of Radiometals for Medical Applications. The Case of Sc as ExampleTherapeutic Radiometals: Worldwide Scientific Literature Trend Analysis (2008⁻2018)14 MeV Neutrons for 99Mo/99mTc Production: Experiments, Simulations and Perspectives.An alternative approach to the preparation of (188)Re radiopharmaceuticals from generator-produced [(188)ReO(4)](-): efficient synthesis of (188)Re(V)-meso-2,3-dimercaptosuccinic acidSynthesis of a novel class of nitrido Tc-99m radiopharmaceuticals with phosphino-thiol ligands showing transient heart uptakeLabeling of fatty acid ligands with the strong electrophilic metal fragment [99mTc(N)(PNP)]2+ (PNP=diphosphane ligand)The crucial role of the diphosphine heteroatom X in the stereochemistry and stabilization of the substitution-inert [M(N)(PXP)]2+ metal fragments (M = Tc, Re; PXP = diphosphine ligand)Whole-body biodistribution and radiation dosimetry of the new cardiac tracer 99mTc-N-DBODCPEGylated N-methyl-S-methyl dithiocarbazate as a new reagent for the high-yield preparation of nitrido Tc-99m and Re-188 radiopharmaceuticalsAutomated preparation of Re-188 lipiodol for the treatment of hepatocellular carcinoma
P50
Q37731314-4BAA7474-E71A-481F-BE35-CED6347C5E23Q38616780-AD8C60B2-DC1C-4921-8FF8-8EF2AF1B021FQ38980175-281CAD88-D37A-4E36-AB6F-25F30BC93612Q39263247-740510D9-893F-41D3-BC5D-79256C0BAB22Q41606679-0EC8D565-E22A-4CDF-92CC-77308063BE7CQ41688002-5B65DFBB-872D-413F-8641-D0DAD4A9F13EQ44140460-4F3B34D6-923C-4C62-95F8-CE001622D98DQ44454353-4B9583A3-8DAC-4681-BADC-C44B36C73097Q44660408-CFD2E314-9008-4166-B411-E4C46B1904FCQ44945588-9979FC18-D981-4959-B8B7-2A0C07CC51BCQ45017368-7726A3FE-0439-401F-959A-D92BF2037993Q46199618-F0E7B5E7-9BD2-4388-8C07-D76F33AF2536Q51733682-1F739475-A3F2-47FF-90B8-D62A94C5C40AQ53008761-4BD9A62C-55E6-4271-B230-8C20B5CEEE10Q53414252-B5C6B362-9F30-455E-BB96-DA9E376E9CFFQ56335374-DBEB4BB1-061C-45D3-A6C1-23BA36E90D9BQ60647012-34D2C7A7-DF97-4336-A6FA-C99E98C229E9Q60766483-ADE56690-125F-4267-B319-2F863D7EB36EQ61455814-BA4FCC99-B119-4B0A-9C92-D1FDC745A40EQ61813619-B7A791F2-5A26-4CA9-A2A6-F6EC9850B03EQ64081419-0477D1E8-9FB8-4406-A8C8-85FF7D468A5EQ64269848-9CA208A6-AD82-40F9-BE89-FE8460BF728FQ64270318-8F495833-79DE-4FE3-BD9E-0B3015F9B250Q64951400-B9C064C5-0D79-4FDA-90E7-C825BE6E0AC7Q73835652-34C69BA5-2138-4400-A270-E293F708A234Q74154305-C1F5D413-BD06-40B2-BC73-78487C97EEF4Q80515170-02B9FDCB-CEE2-4FB8-9587-F1D14BE8DB1CQ81161971-DB7C9DEB-5300-4EA7-83EF-D6381E1915DCQ81653156-1AC67566-4370-46DA-A829-520457874131Q82339809-BF42E92C-AEEA-46E5-95D6-8E47C4805C14Q83398671-72F79B82-EF7C-4292-8E9E-4468D0AA6512
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alessandra Boschi
@ast
Alessandra Boschi
@en
Alessandra Boschi
@es
Alessandra Boschi
@nl
type
label
Alessandra Boschi
@ast
Alessandra Boschi
@en
Alessandra Boschi
@es
Alessandra Boschi
@nl
prefLabel
Alessandra Boschi
@ast
Alessandra Boschi
@en
Alessandra Boschi
@es
Alessandra Boschi
@nl
P106
P1153
7006668214
P21
P31
P496
0000-0002-6382-1944